Shares in Allergy Therapeutics changed hands at about 5.50p on 4 August 2026, down roughly 4.7% on the day and valuing the AIM-listed biotech at around £361m. The fall echoes a wider slide that has more than halved the stock from its February peak, leaving it close to a 52-week low even after an encouraging late-July trading update. A recapitalised, Grassmuno-launching business is growing revenue, yet the market has yet to be convinced the recovery is on track.
Introduction
Allergy Therapeutics plc (AIM: AGY) is a West Sussex-based biotechnology company that develops allergy immunotherapies — treatments that expose patients to carefully controlled, escalating doses of an allergen to retrain the immune system and dampen its over-reaction. The supplied headline points to a 4.7% slide. On 4 August 2026 the shares traded at about 5.50p, down roughly 4.68% (0.28p) on the day, so on this occasion the screener-style snapshot and the latest session broadly coincide. That leaves the group valued at approximately £361m across some 6.33 billion shares in issue.
Yet the day's move is a footnote to a much larger reversal. From a 52-week high of 12.10p on 26 February 2026, the stock has more than halved, touching a low of 5.25p on 23 July before steadying. This article separates the headline percentage from the latest price, the single session from the six-month trend, and confirmed corporate developments from market noise, while asking why a recapitalised, revenue-growing business remains so unloved.
Reading the share-price move
The 4.7% figure is best read as a screener-style reading rather than a definitive statement of cause. In this instance it happens to sit close to the latest one-day fall, but the more important signal is the trajectory. Having peaked above 12p in late February, the shares have shed well over half their value in barely five months and now trade within touching distance of their 52-week low. Past performance is not a reliable indicator of future results, and a falling chart says nothing on its own about the health of the underlying business.
Crucially, no single company-specific catalyst had been officially confirmed at the time of writing. The drift lower has coincided with generally cautious sentiment towards small-cap biotech and with profit-taking after a strong early-2026 run, but correlation should not be mistaken for causation. The most recent hard news — a late-July trading update — was, if anything, encouraging, which makes the share-price weakness all the more striking.
A rescue, a recapitalisation and real dilution
To understand the scepticism, it helps to recall how close Allergy Therapeutics came to the brink. In 2023 the company undertook an emergency recapitalisation after warning over its ability to continue as a going concern — the accounting judgement about whether a business has sufficient resources to keep trading for at least the next 12 months. That rescue, and the refinancing that followed, kept the lights on but came at a heavy cost to existing holders.
The clean-up culminated in October 2025, when investors SkyGem Acquisition Limited and Southern Fox Investments Limited exercised 1.38 billion lender warrants, injecting about £55m that was used to repay the shareholder loan and clear all outstanding debt. A fresh £50m unsecured facility, available until 2030, was agreed with the same backers, and a separate £40m senior secured facility was later struck with specialist lender Hayfin. The trade-off was dilution: the warrant exercise lifted the share count to just over 6.14 billion, so each existing share now represents a smaller slice of the company. A stronger balance sheet was bought with a much larger register.
Grassmuno: the commercial engine
The recovery thesis rests on Grassmuno, the commercial name for Grass MATA MPL, the group's flagship grass-pollen immunotherapy. On 16 December 2025 Germany's Paul-Ehrlich-Institut granted the product full marketing authorisation — formal regulatory approval to sell a medicine — making it the first subcutaneous (injected) grass-pollen immunotherapy cleared under Germany's TAV regime, the Therapieallergene-Verordnung framework that is progressively bringing established allergy products through modern licensing.
That approval leaned on late-stage clinical evidence, including the pivotal G306 Phase III trial. A Phase III trial is the large, final human study, typically comparing a treatment against a placebo, that regulators require before approval; G306 showed a statistically significant reduction in patients' combined symptom-and-medication score during peak pollen season. Grassmuno launched mid-season in Germany in the first quarter of 2026, and management is counting on it to anchor growth in the company's largest market.
The late-July trading update
The most recent confirmed development came on 29 July 2026, when Allergy Therapeutics issued an unaudited trading update for the year to 30 June 2026. It reported revenue of about £59.9m, up 9% on a reported basis — roughly 5% at constant currency, which strips out exchange-rate effects — with second-half sales of around £23.6m growing more than 12%. Year-end cash had almost doubled to £24.2m, from £12.8m, reflecting the refinancing.
Management guided to double-digit reported revenue growth in the year to June 2027 — a forecast, not a guarantee — as Germany's TAV transition concludes in October 2026 and Grassmuno enjoys its first full selling season. These figures are unaudited and remain subject to the full-year results; investors should treat forward guidance as an estimate that may not be realised.
Pipeline and the peanut vaccine
Beyond grass pollen, the pipeline's headline asset is VLP Peanut, a short-course peanut-allergy vaccine that has reported Phase I/IIa data — early-stage human testing focused primarily on safety and immune response rather than definitive efficacy. The programme met its primary safety endpoint, but it remains years from any potential market. Early-stage biotech assets carry binary risk: a single disappointing read-out or regulatory setback can erase much of the value the market ascribes to them, while success can transform the picture.
Risks: cash runway and binary outcomes
Several risks deserve emphasis. Although cash has improved, an immunotherapy developer with a substantial research-and-development budget must watch its runway — the length of time existing funds will last — and the group retains sizeable undrawn facilities precisely because further funding may be needed. Any future draw or equity raise would add to an already heavily diluted register. Commercially, the business is concentrated in Germany and dependent on the successful commercial ramp of a single lead product. Clinically and regulatorily, outcomes are binary: trial results and approval decisions tend to move the shares sharply in either direction. A mooted dual primary listing in Hong Kong, meanwhile, remains exploratory and unconfirmed.
What it means for investors
For now, Allergy Therapeutics presents a genuine tension. The operational signals — a growing top line, an approved and launching flagship product, a repaired balance sheet — point one way; the share price, more than 50% below its February high, points the other. No single company-specific catalyst had been officially confirmed at the time of writing to explain the latest fall, and the weakness looks more consistent with broad small-cap caution and post-dilution digestion than with any fresh operational shock. Whether this proves a delayed recovery or a value trap will hinge on execution in the FY27 selling season. Past performance is not a reliable indicator of future results, and nothing here constitutes personal financial advice.
_11_18_2026_06_43_20_247880.jpg)





Please wait processing your request...